{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T23:51:49Z","timestamp":1774050709571,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"MUSC-CTSA"},{"name":"National Institutes of Health National Center for Advancing Translational Sciences","award":["UL1 TR001450"],"award-info":[{"award-number":["UL1 TR001450"]}]},{"name":"Onyx-Amgen"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.bbmt.2018.01.036","type":"journal-article","created":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T03:41:01Z","timestamp":1517542861000},"page":"1379-1385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Phase 1\/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed\/Refractory Multiple Myeloma"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5362-2469","authenticated-orcid":false,"given":"Luciano J.","family":"Costa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather J.","family":"Landau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saurabh","family":"Chhabra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parameswaran","family":"Hari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Racquel","family":"Innis-Shelton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly N.","family":"Godby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roni","family":"Tamari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Anderton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio A.","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2018.01.036_bib0010","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.01.036_bib0015","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.01.036_bib0020","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","article-title":"Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial","volume":"16","author":"Gay","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2018.01.036_bib0025","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood.V128.22.673.673","article-title":"Intensification therapy with bortezomib-melphalan-prednisone versus autologous stem cell transplantation for newly diagnosed multiple myeloma: an intergroup, multicenter, phase III study of the European Myeloma Network (EMN02\/HO95 MM Trial)","volume":"128","author":"Cavo","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.036_bib0030","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.01.036_bib0035","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Fran\u00e7ais du My\u00e9lome","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.01.036_bib0040","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3026(16)30049-7","article-title":"The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT\/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial","volume":"3","author":"Cook","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.bbmt.2018.01.036_bib0045","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.bbmt.2013.01.004","article-title":"Salvage second hematopoietic cell transplantation in myeloma","volume":"19","author":"Michaelis","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.036_bib0050","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.bbmt.2013.08.002","article-title":"Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma","volume":"19","author":"Costa","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.036_bib0055","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/j.bbmt.2016.08.017","article-title":"A phase I\/II study of escalating doses of bortezomib in conjunction with high-dose melphalan as a conditioning regimen for salvage autologous peripheral blood stem cell transplantation in patients with multiple myeloma","volume":"22","author":"Biran","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.036_bib0060","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.01.036_bib0065","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.01.036_bib0070","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.01.036_bib0075","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood-2009-06-229658","article-title":"Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM)","volume":"115","author":"Roussel","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.036_bib0080","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","article-title":"Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome","volume":"67","author":"Demo","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2018.01.036_bib0085","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-10-1950","volume":"17","author":"Arastu-Kapur","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2018.01.036_bib0090","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2018.01.036_bib0095","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.bbmt.2018.01.036_bib0100","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood.V99.3.731","volume":"99","author":"Moreau","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.036_bib0105","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.3324\/haematol.2010.028027","article-title":"Busulfan 12\u2009mg\/kg plus melphalan 140\u2009mg\/m2 versus melphalan 200\u2009mg\/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA\/GEM2000 study","volume":"95","author":"Lahuerta","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2018.01.036_bib0110","doi-asserted-by":"crossref","first-page":"9367","DOI":"10.1158\/0008-5472.CAN-09-2616","article-title":"Targeting the Fanconi anemia\/BRCA pathway circumvents drug resistance in multiple myeloma","volume":"69","author":"Yarde","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2018.01.036_bib0115","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1158\/1078-0432.CCR-10-1662","article-title":"A phase I\/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study","volume":"16","author":"Lonial","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2018.01.036_bib0120","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.bbmt.2016.03.021","article-title":"Busulfan, melphalan, and bortezomib versus high-dose melphalan as a conditioning regimen for autologous hematopoietic stem cell transplantation in multiple myeloma","volume":"22","author":"Rodriguez","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.036_bib0125","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1365-2141.2012.09099.x","article-title":"Bortezomib salvage followed by a phase I\/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma","volume":"157","author":"Nishihori","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2018.01.036_bib0130","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood-2012-09-451872","article-title":"A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinical Trials Group Myeloma 10 Trial","volume":"121","author":"Stewart","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.036_bib0135","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.036_bib0140","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJMoa053583","article-title":"Thalidomide and hematopoietic-cell transplantation for multiple myeloma","volume":"354","author":"Barlogie","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.01.036_bib0145","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood-2009-05-222539","article-title":"A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma","volume":"115","author":"Lokhorst","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.036_bib0150","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/ajh.23274","article-title":"Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma","volume":"87","author":"Maiolino","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2018.01.036_bib0155","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/blood-2015-11-683854","article-title":"CHAMPION-1: a phase 1\/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma","volume":"127","author":"Berenson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.036_bib0160","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.01.036_bib0165","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","article-title":"A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma","volume":"120","author":"Jakubowiak","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.036_bib0170","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1182\/blood.V128.22.2110.2110","article-title":"Final results from a multicenter, open-label, dose-escalation phase 1b\/2 study of single-agent oprozomib in patients with hematologic malignancies","volume":"128","author":"Ghobrial","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.036_bib0175","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2018.01.036_bib0180","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1038\/leu.2017.122","article-title":"Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes","volume":"31","author":"Hari","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.01.036_bib0185","doi-asserted-by":"crossref","first-page":"e283","DOI":"10.1016\/S2352-3026(17)30080-7","article-title":"High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan","volume":"4","author":"Nieto","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.bbmt.2018.01.036_bib0190","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/bmt.2015.125","article-title":"Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial","volume":"50","author":"Gimsing","year":"2015","journal-title":"Bone Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118300533?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118300533?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:01:24Z","timestamp":1761058884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879118300533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S1083879118300533"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.01.036","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 1\/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed\/Refractory Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.01.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}